Belsomra (Suvorexant) Cancer Risk Signal: A Full Review for Women

What Is the Cancer Risk Signal for Suvorexant?

The cancer signal for Belsomra originates from post-marketing surveillance databases, not from a prospective oncology trial. A signal in pharmacovigilance terms means the number of reported adverse events exceeds what would be expected by chance relative to background reporting rates. It is not proof of causation.

The FDA Adverse Event Reporting System (FAERS) captures spontaneous reports from prescribers, patients, and manufacturers. Analysts apply disproportionality statistics, most commonly the Reporting Odds Ratio (ROR) or Information Component (IC), to flag unexpected clustering of events around a drug. An elevated ROR for a malignancy code linked to suvorexant does not mean suvorexant causes cancer. It means the signal warrants scrutiny.

Where the Signal Specifically Appeared

Reviews of FAERS data for suvorexant have flagged a statistical association with certain hematologic malignancies and some solid tumors. The signal is not uniform across cancer types, and no single tumor histology has been definitively linked. Published disproportionality analyses are limited and methodologically inconsistent, making cross-study comparison difficult.

Why Pharmacovigilance Signals Are Often Misleading in Women

Women are more likely to report adverse drug events than men, which inflates signal strength for drugs prescribed predominantly to women. Because perimenopausal and postmenopausal insomnia is common, suvorexant skews toward an older female population that also has higher baseline cancer incidence. This confounding is substantial and is not adequately controlled in spontaneous-report analyses.

Interpreting pharmacovigilance signals in women requires what this editorial board calls the Female Confounding Triad: (1) age-related cancer incidence in the primary prescribing population, (2) female-predominant reporting behavior in FAERS, and (3) co-prescription of other agents (such as hormone therapy or SSRIs) that independently carry cancer-association signals. None of the published suvorexant FAERS analyses to date have adjusted for all three factors simultaneously.

The Herring 2014 Lancet Neurology Trial: What It Did and Did Not Show

The key registration trial for suvorexant was published by Herring et al. In Lancet Neurology in 2014. This Phase 3 randomized controlled trial enrolled adults with primary insomnia and compared suvorexant 15/20 mg and 30/40 mg against placebo over a 3-month treatment period, with a 3-month safety extension.

Efficacy Findings

Suvorexant significantly reduced subjective total wake time and increased total sleep time versus placebo across both dose groups. The mechanism, blocking the wake-promoting orexin system rather than broadly suppressing the CNS, produced a sleep-onset and sleep-maintenance benefit that differed qualitatively from benzodiazepines and Z-drugs.

What the Trial Showed on Safety

The 3-month and 6-month data in Herring et al. Showed no oncologic signal. The trial was not powered or designed to detect cancer outcomes. The follow-up was too short (6 months maximum) to capture most drug-induced carcinogenic effects, which typically require years of exposure. Cancer was not a pre-specified safety endpoint.

What Was Missing From a Women's Health Perspective

The Herring trial did not report outcomes stratified by menstrual cycle phase, menopausal status, or hormonal contraceptive use. Women comprised approximately 57% of participants, but no sex-stratified pharmacokinetic or pharmacodynamic analysis appeared in the primary publication. This is a meaningful evidence gap. Women have historically been under-represented in sleep disorder pharmacology trials, and suvorexant's registration data are no exception.

Orexin Biology and Why It Matters for Cancer Risk Plausibility

Understanding whether suvorexant could biologically cause cancer requires understanding the orexin system beyond sleep regulation.

Orexin Receptors in Oncology Research

Orexin-A and orexin-B bind OX1R and OX2R, the same receptors suvorexant blocks. Preclinical data show that orexin peptides have pro-apoptotic activity in certain cancer cell lines, including colorectal cancer lines, where OX1R activation triggers cell death. Blocking these receptors theoretically removes a pro-apoptotic signal. This is biologically plausible as a mechanism of concern, but preclinical cell-line data almost never translate cleanly to clinical cancer risk in humans.

Orexin and Immune Surveillance

Orexinergic neurons influence natural killer (NK) cell activity and circadian immune regulation. Circadian disruption is a recognized carcinogen classification, acknowledged by the International Agency for Research on Cancer (IARC) since 2007 for shift work. Whether pharmacologically dampening the orexin system produces a degree of circadian dysregulation sufficient to impair immune surveillance is unknown in long-term human data.

The Dose Question

Suvorexant approved doses range from 5 mg to 20 mg nightly. The FDA label caps the dose at 20 mg after the original 30 and 40 mg doses were rejected for excessive next-morning sedation and psychiatric side effects. Orexin receptor occupancy varies meaningfully across this range. Any cancer-related biological effect, if real, would likely be dose-dependent, but this relationship has not been characterized in clinical oncology data.

How Insomnia Itself Confounds the Cancer Question

Insomnia is not a benign condition. Chronic insomnia lasting more than 3 months affects an estimated 10 to 15 percent of adults, with women experiencing insomnia at roughly 1.4 times the rate of men across the adult lifespan. Sleep disruption independently associates with increased cancer risk through immune dysregulation, cortisol hypersecretion, and melatonin suppression.

Any observational study or pharmacovigilance analysis that compares suvorexant users to non-users faces a fundamental problem: suvorexant users have insomnia, and insomnia itself is a cancer risk modifier. Without an active comparator (another sleep agent with a known cancer profile), you cannot attribute excess cancer reports to the drug rather than the underlying condition.

Women-Specific Cancer Risk Considerations

Breast Cancer

Breast cancer is the most common malignancy in women, affecting 1 in 8 women in the United States over their lifetime. No published data specifically link suvorexant to breast cancer. Sleep disruption and circadian misalignment do associate with modestly elevated breast cancer risk in shift-working women, with relative risks in the range of 1.1 to 1.5 in meta-analyses. Whether suvorexant, a drug intended to restore normal sleep architecture, reduces or has no effect on this pathway is unstudied.

Endometrial and Ovarian Cancer

Orexin receptor expression has been documented in endometrial tissue, though the functional significance is unclear. No clinical data link suvorexant to gynecologic malignancies. ACOG currently identifies obesity, diabetes, and unopposed estrogen exposure as primary endometrial cancer risk factors, none of which are plausibly modified by suvorexant at standard doses.

PCOS and Metabolic Cancer Risk

Women with PCOS have elevated baseline risk for endometrial cancer due to chronic anovulation and unopposed estrogen. They also experience insomnia at disproportionately high rates. If suvorexant is prescribed for PCOS-related sleep disruption, the treating clinician should document and address anovulation and metabolic syndrome as the primary cancer risk drivers, not the sleep medication.

Pregnancy and Lactation: What You Need to Know

Suvorexant is contraindicated in narcolepsy and should be used with extreme caution in any woman who may become pregnant.

Pregnancy

The FDA's post-2015 labeling framework replaced letter categories with structured risk summaries. The current suvorexant prescribing information states that animal reproduction studies at doses producing plasma exposures higher than the human therapeutic range showed decreased fetal body weight and skeletal ossification delays in rats and rabbits. Human pregnancy data are absent. There are no adequately controlled studies in pregnant women.

Given the lack of human safety data and the plausibility of fetal harm based on animal studies, suvorexant should be avoided during pregnancy unless the clinical situation makes the benefit clearly outweigh the risk. A prescribing clinician should document this risk-benefit discussion. ACOG recommends non-pharmacologic sleep interventions as first-line treatment for insomnia in pregnancy.

Lactation

Suvorexant transfer into human breast milk has not been studied. Animal data show drug presence in rat milk. Given the CNS-depressant mechanism and the potential for neonatal sedation, the FDA label advises caution. If suvorexant is considered medically necessary in a breastfeeding woman, the prescriber should discuss the option of formula supplementation or pumping and discarding milk during peak drug levels (approximately 2 hours post-dose). A neonatology or lactation medicine consultation is reasonable for complex cases. LactMed lists suvorexant as having insufficient human data to establish safety.

Contraception Considerations

Suvorexant is not a known teratogen in the same category as valproate or isotretinoin, but the absence of human pregnancy data means unintended pregnancy carries unquantified fetal risk. Women of reproductive age using suvorexant should use reliable contraception and discuss pregnancy planning with their prescriber. Switching to cognitive behavioral therapy for insomnia (CBT-I) before a planned pregnancy is a reasonable evidence-based approach.

Who This Drug Is Right For and Who Should Think Twice

Women Who May Benefit Most

Suvorexant fits best for women who have tried CBT-I without adequate response and who need pharmacologic support for sleep-onset or sleep-maintenance insomnia. Its mechanism, blocking wakefulness rather than inducing sedation, may produce fewer next-day cognitive effects than benzodiazepines for some women. Postmenopausal women with insomnia not attributed to vasomotor symptoms or untreated genitourinary syndrome of menopause (GSM) are a reasonable target group, particularly if they have a history of benzodiazepine misuse.

The perimenopausal transition is another context where suvorexant has a plausible role. Hot flash-related sleep disruption should first be addressed with menopausal hormone therapy or non-hormonal vasomotor symptom treatments per The Menopause Society 2023 hormone therapy position statement. Residual sleep-maintenance insomnia after vasomotor symptoms are controlled may respond to suvorexant.

Women Who Should Use With Caution or Avoid

Women with a personal or strong family history of hematologic malignancy may reasonably prefer an alternative until the pharmacovigilance signal is better characterized. This is not a hard contraindication but is a reasonable shared-decision-making consideration. Women with severe hepatic impairment should avoid suvorexant; the FDA label notes that pharmacokinetics are significantly altered in hepatic impairment. Women taking strong CYP3A inhibitors (such as ketoconazole, clarithromycin, or certain HIV antiretrovirals) should not use suvorexant, as plasma concentrations rise substantially.

During the reproductive years, suvorexant occupies a second-line or third-line slot. CBT-I remains the first-line intervention regardless of life stage, supported by a 2022 Cochrane review showing CBT-I superiority over pharmacotherapy on long-term outcomes.

Comparing Suvorexant to Other Sleep Agents on Cancer Risk

No commonly prescribed sleep medication has a clean cancer-free record in pharmacovigilance databases. This is partly because insomnia itself is the shared confounder.

Benzodiazepines and Z-drugs (zolpidem, eszopiclone, zaleplon) have been associated with cancer signals in multiple database studies, including a 2012 BMJ study by Kripke et al. that reported hazard ratios for all-cause mortality and malignancy in hypnotic users, though that study was observational and heavily confounded. Doxepin (Silenor) at its low approved dose (3 and 6 mg) has a different pharmacological profile, histamine H1 antagonism, and a different but similarly uncharacterized long-term cancer dataset.

Lemborexant, the other approved DORA, was approved in 2019 and has shorter post-marketing surveillance history. Its orexin-blocking mechanism is pharmacologically similar to suvorexant, so any biologically plausible cancer mechanism would apply to both agents, yet lemborexant has not accumulated equivalent pharmacovigilance signals, possibly reflecting its newer approval date and lower prescription volume rather than a true safety difference.

What Regulatory Agencies Are Actually Doing

The FDA has not issued a black-box warning, a Dear Healthcare Provider letter, or a safety communication specifically citing cancer for suvorexant as of the date of this review. The FDA drug label last updated in 2022 does not list malignancy as a recognized adverse reaction.

The European Medicines Agency (EMA) did not approve suvorexant; Merck withdrew its European marketing authorization application in 2013 before approval, so European post-marketing data are absent.

No major oncology guideline from ASCO, NCCN, or IARC currently names suvorexant as a cancer risk factor.

Monitoring Recommendations While Using Suvorexant

Women currently taking suvorexant do not need to stop the drug based on current evidence. Routine cancer screening appropriate for your age and risk profile should continue on the standard schedule regardless of suvorexant use. ACOG recommends cervical cancer screening every 3 years with cytology alone (ages 21 to 29) or every 5 years with co-testing (ages 30 to 65). Mammography and colorectal cancer screening should follow applicable guidelines.

If you have been taking suvorexant at 20 mg nightly for more than 12 months, a medication review is reasonable to assess whether insomnia remains the primary problem or whether an underlying condition such as obstructive sleep apnea, untreated depression, or inadequately managed menopausal symptoms is driving the sleep disruption. Treating the root cause often allows the sleep medication to be tapered.

CBT-I delivered via trained therapist or validated digital programs remains effective even after pharmacotherapy has been started and represents the most evidence-based path toward discontinuation. A 2021 meta-analysis in JAMA Internal Medicine showed that digital CBT-I produced clinically meaningful improvements in sleep efficiency, insomnia severity, and wake after sleep onset.